Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Pharma
J&J reports $133M in sales for new multiple myeloma med Tecvayli
For the first time, J&J is reporting sales of Tecvayli, which is off to a strong launch and contributing to the company's power in multiple myeloma.
Kevin Dunleavy
Apr 16, 2024 11:28am
Top 20 pharma companies by 2023 revenue
Apr 15, 2024 3:00am
FDA weighs another approvable myeloma endpoint. What's at stake?
Apr 9, 2024 9:00am
J&J, Legend's Carvykti quickly leaps ahead of BMS' rival CAR-T
Apr 8, 2024 8:30am
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
Apr 5, 2024 8:25am
FDA OKs Basilea's antibiotic Zevtera for 3 types of infections
Apr 4, 2024 8:45am